Satyor (gosogliptin) / ChemRar, Pfizer - LARVOL DELTA

Molecular and pharmacological impacts of phytochemicals on the enoyl-acyl carrier protein reductase: potential therapeutic implications in tuberculosis. (PubMed, Integr Biol (Camb)) - "Among 42 screened phytocompounds, the top five (Ebastine, 2-Phenylaminoadenosine, Gosogliptin, Lorcainide, and Levomefolic acid) showed promising binding affinities towards InhA (PDB: 2X22), with binding free energy ranging from -9.6 to -10.9 kcal/mol. Computational tools such as molecular docking, molecular dynamics simulations, and predictive toxicology models, provides a rational framework for selecting promising leads for further experimental validation. This integrated approach not only facilitates the translation of traditional medicinal plant knowledge into evidence-based drug discovery but also maximizes the efficiency of the drug development pipeline."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Evaluation and comparison of efficacy and safety of mitochondrial modulator (Imeglimin) and DPP-4 inhibitors in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis. (PubMed, J Endocrinol Invest) - "Imeg and DPP-4i demonstrated favorable antidiabetic effects and good safety. Imeg exhibited comparable glycemic control to that of DPP-4i. Overall, Alog was the most suitable option among the included DPP-4i for T2DM patients with hyperlipidemia. Tene demonstrated significant efficacy in glycemic control, and can be a first-line choice among the included DPP-4i."

Clinical • Journal • Retrospective data • Review • Diabetes • Dyslipidemia • Infectious Disease • Metabolic Disorders • Type 2 Diabetes Mellitus

Drug Development. (PubMed, Alzheimers Dement) - "The clinically approved DPP-4Is, sitagliptin (Januvia) and PF-00734200 (gosogliptin/Saterex) were hence evaluated in the classic 6-OHDA unilateral medial forebrain bundle rat PD model to evaluate their repurposing potential when administered as human equivalent oral doses...Sitagliptin/PF-00734,200 pre- or post-treatment mitigated 6-OHDA-induced dopaminergic neurodegeneration, dopamine level loss and neuroinflammation, and augmented neurogenesis in lesioned substantia nigra pars compacta and in striatum, and reduced classical methamphetamine-induced rotation in rats...Incretin mimetics are already in clinical evaluation in PD and AD. Similarly, the repurposing of gliptins warrants evaluation both alone and in combination with an effective incretin mimetic."

Journal • Alzheimer's Disease • CNS Disorders • Diabetes • Inflammation • Metabolic Disorders • Movement Disorders • Parkinson's Disease • Type 2 Diabetes Mellitus

Elevating brain GLP-1 and GIP levels as a treatment strategy for neurodegenerative disorders (AAIC 2024) - "The clinically approved DPP-4Is, sitagliptin ( Januvia ) and PF-00734200 (gosogliptin/ Saterex ) were hence evaluated in the classic 6-OHDA unilateral medial forebrain bundle rat PD model to evaluate their repurposing potential when administered as human equivalent oral doses... Sitagliptin/PF-00734,200 pre- or post-treatment mitigated 6-OHDA-induced dopaminergic neurodegeneration, dopamine level loss and neuroinflammation, and augmented neurogenesis in lesioned substantia nigra pars compacta and in striatum, and reduced classical methamphetamine-induced rotation in rats... These studies support further evaluation of repurposing clinically approved drugs that elevate plasma/brain/CSF GLP-1/GIP as a treatment strategy for neurodegenerative disorders. Incretin mimetics are already in clinical evaluation in PD and AD. Similarly, the repurposing of gliptins warrants evaluation both alone and in combination with an effective incretin mimetic."

Alzheimer's Disease • CNS Disorders • Diabetes • Inflammation • Metabolic Disorders • Movement Disorders • Parkinson's Disease • Type 2 Diabetes Mellitus